Biohaven (BHVN): Valuation Check After Encouraging BHV-1510 Immuno-Oncology Data at ESMO Congress [Yahoo! Finance]
Biohaven Pharmaceutical Holding Company Ltd. Common Shares (BHVN)
Last biohaven pharmaceutical holding company ltd. common shares earnings: 2/25 04:45 pm
Check Earnings Report
US:NYSE Investor Relations:
investors.biohavenpharma.com
Company Research
Source: Yahoo! Finance
See our latest analysis for Biohaven. Despite the buzz around BHV-1510, Biohaven's 1 month share price return of 14.7% comes after a steep year to date share price drop of around 70 percent, and a similar 1 year total shareholder return decline, so sentiment is stabilising from a low base rather than breaking into a clear uptrend. If this oncology update has you rethinking your healthcare exposure, it could be a good moment to explore other potential candidates in healthcare stocks With Biohaven trading more than 80 percent below consensus targets despite headline grabbing trial data, is the market overlooking a still early stage pipeline, or already baking in all the future oncology growth? Biohaven's latest close at $10.85 sits alongside a headline price to book ratio of around -83.9x, a figure that immediately looks extreme versus peers. The price to book multiple compares the market value of a company's equity to its accounting book value. For asset heavy or loss making
Show less
Read more
Impact Snapshot
Event Time:
BHVN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BHVN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BHVN alerts
High impacting Biohaven Pharmaceutical Holding Company Ltd. Common Shares news events
Weekly update
A roundup of the hottest topics
BHVN
News
- Biohaven (BHVN) Is Down 5.9% After New BHV-1510 Combo Data - What's Changed [Yahoo! Finance]Yahoo! Finance
- Biohaven Presents Clinical Safety and Efficacy Data for BHV-1510, a Next-Generation Trop2 Antibody Drug Conjugate in Combination with Cemiplimab at the 2025 European Society for Medical Oncology (ESMO) Immuno-Oncology Congress [Yahoo! Finance]Yahoo! Finance
- Biohaven Presents Clinical Safety and Efficacy Data for BHV-1510, a Next-Generation Trop2 Antibody Drug Conjugate in Combination with Cemiplimab at the 2025 European Society for Medical Oncology (ESMO) Immuno-Oncology CongressPR Newswire
- Biohaven (NYSE:BHVN) was downgraded by analysts at HC Wainwright from a "buy" rating to a "neutral" rating.MarketBeat
- Biohaven (BHVN): Assessing Valuation After Recent Share Price Boost [Yahoo! Finance]Yahoo! Finance
BHVN
Earnings
- 11/10/25 - Beat
BHVN
Sec Filings
- 11/18/25 - Form 4
- 11/17/25 - Form 4
- 11/17/25 - Form 4
- BHVN's page on the SEC website